Summary by Futu AI
TransCode Therapeutics, Inc. (TransCode) has announced the filing of a DEFR14A form with the United States Securities and Exchange Commission (SEC), which includes a Proxy Statement and an amendment to the company's Definitive Proxy Statement on Schedule 14A. The Proxy Statement, filed on May 20, 2024, outlines proposals for the upcoming 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The key proposals include the election of four directors, approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split of common stock at a ratio ranging from 1:2 to...Show More